What alternative oral contraceptive formulations can be used instead of Brevicon?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Alternative Oral Contraceptives to Brevicon

For women seeking alternatives to Brevicon (norethindrone 0.5mg/ethinyl estradiol 35mcg), the best options are low-dose monophasic combined oral contraceptives containing 30-35 μg ethinyl estradiol with levonorgestrel or norgestimate as the progestin component.

First-Line Alternatives

Standard Ethinyl Estradiol-Based COCs

The most straightforward alternatives are other low-dose ethinyl estradiol (EE) formulations 1:

  • 30-35 μg EE + levonorgestrel - This represents the most evidence-based alternative with the lowest thrombotic risk among combined hormonal contraceptives 2
  • 30-35 μg EE + norgestimate - Another well-studied second-generation progestin option with favorable safety profile 1

These monophasic formulations are preferred because they provide consistent hormone levels and allow for easier cycle extension if needed for conditions like dysmenorrhea or endometriosis 1.

Important safety consideration: Second-generation progestins (levonorgestrel, norgestimate) carry lower venous thromboembolism risk compared to third-generation progestins (desogestrel, gestodene) or specific progestins like drospirenone and cyproterone acetate 2.

Newer Natural Estrogen Alternatives

17β-Estradiol-Based Formulations

For women requiring contraception who may benefit from natural estrogens over synthetic ethinyl estradiol 3, 2:

  • 17β-estradiol 1.5mg + nomegestrol acetate (Zoely) - Monophasic formulation with 24 active pills 2, 4
  • Estradiol valerate + dienogest (Qlaira/Natazia) - Quadriphasic regimen with doses ranging 1-3mg estradiol valerate 2, 5

These natural estrogen formulations may offer theoretical advantages in terms of hepatic metabolism and potentially lower thrombotic risk, though long-term safety data remain limited compared to traditional EE-based pills 6, 7.

Non-Oral Alternatives

Transdermal Options

Contraceptive patch (levonorgestrel 120 μg/day + ethinyl estradiol 30 μg/day) - Weekly application for 3 weeks followed by patch-free week 8

Critical limitation: Reduced efficacy in women with BMI ≥30 kg/m² (Pearl Index 8.6 vs 4.3 in women with BMI <30) 8. Contraindications are identical to oral combined contraceptives 2.

Vaginal Ring

NuvaRing (etonogestrel 120 μg/day + ethinyl estradiol 15 μg/day) - Inserted for 3 weeks, removed for 1 week 1. Offers simplest regimen with comparable efficacy and side effect profile to COCs.

Progestin-Only Options

For women with contraindications to estrogen-containing contraceptives 2:

  • Desogestrel 0.075mg daily (Cerazette) - More effective ovulation inhibition than older progestin-only pills
  • Levonorgestrel 0.03mg daily (Microval) - Traditional progestin-only pill
  • Levonorgestrel IUD (Mirena) - 5-year duration, excellent for women with dysmenorrhea or heavy bleeding 2
  • Etonogestrel implant (Nexplanon) - 3-year duration, highest efficacy among reversible methods 2

Key Selection Factors

Cardiovascular Risk Assessment

Absolute contraindications to combined hormonal contraception 2:

  • Smoking >15 cigarettes/day in women >35 years
  • Uncontrolled hypertension
  • Personal history of venous thromboembolism or arterial events
  • Migraine with aura

In these situations, progestin-only methods are mandatory 2.

Metabolic Considerations

For women with diabetes 2:

  • Type 1 without complications: Combined oral contraceptives acceptable if no additional risk factors
  • Type 2 or complicated Type 1: Progestin-only methods preferred (oral progestins, implant, or levonorgestrel IUD)

Practical Considerations

  • Compliance concerns: Consider long-acting reversible contraception (IUD or implant) over daily pills 2
  • Desire for amenorrhea: Extended-cycle COCs or continuous combined formulations 1
  • Acne/hirsutism: Avoid progestin-only methods; consider anti-androgenic progestins (though these carry higher thrombotic risk) 2

Common Pitfalls to Avoid

  1. Do not prescribe third-generation progestins (desogestrel, gestodene) or drospirenone as first-line alternatives - these carry 1.5-2x higher VTE risk than levonorgestrel 2

  2. Do not assume transdermal/vaginal routes are safer - contraindications remain identical to oral formulations despite bypassing first-pass metabolism 2

  3. Do not overlook BMI when prescribing patches - efficacy significantly reduced in women ≥30 kg/m² 8

  4. Do not forget backup contraception - Use barrier methods for 7 days when starting any new hormonal method 1

References

1
Guideline

contraception for adolescents.

Pediatrics, 2014

4
Research

Zoely: a new combined oral contraceptive.

Drug and therapeutics bulletin, 2014

5
Research

An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012

Related Questions

What alternative birth control methods can be used for a female experiencing menorrhagia (heavy menstrual bleeding) while taking Lo Loestrin (ethinyl estradiol and noregestrel)?
In a 26-year-old woman with polymenorrhea every two weeks for one year, who has not responded to the combined oral contraceptive Nexstellis (ethinyl estradiol/levonorgestrel) and has a normal pelvic ultrasound, what is the next step in management?
What are the indications, dosing schedule, contraindications, and precautions for Alesse (ethinyl estradiol/levonorgestrel) oral contraceptive?
What non‑oral, non‑hormonal contraceptive methods are available?
What birth control options are suitable for a 13-year-old?
In a patient receiving lurasidone who has forceful, repetitive blinking, is this more likely tardive dyskinesia (TD) or extrapyramidal symptoms (EPS)?
For a female patient requiring testosterone replacement, should I start with the 2 mg/24‑hour transdermal testosterone patch or the 5 mg/24‑hour patch?
What is the appropriate management for bleeding after a prostate biopsy?
In a patient who was trialed on benztropine 2 mg daily for one week but developed anticholinergic side effects, and then switched to amantadine 100 mg with no improvement of acute blepharospasm‑type dystonia, what is the recommended next step in management?
Which medical conditions indicate the need for dental antibiotic prophylaxis?
What is the recommended method to switch a patient from levothyroxine 75 µg to NP Thyroid (desiccated thyroid)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.